Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests

Food and Chemical Toxicology

Volumn 48, Issue 12, 2010, Pages 3481-3485

  Schwen, Richard ^a   Jackson, Richard ^a   Proudlock, Raymond ^b  

^a Ausio Pharmaceuticals LLC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Daidzein; Genotoxicity; Micronucleus; Phytoestrogens; S equol

Indexed keywords

EQUOL;

ANIMAL CELL; ARTICLE; BACTERIAL MUTATION; BONE MARROW CELL; CELL ASSAY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SAFETY; DRUG STRUCTURE; ERYTHROPOIESIS; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRONUCLEUS TEST; MUTAGENESIS; NONHUMAN; POLYPLOIDY; RAT; SENSITIVITY ANALYSIS; TOXICITY TESTING;

ANIMALS; BACTERIA; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; FEMALE; ISOFLAVONES; MALE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY; SALMONELLA TYPHIMURIUM;

ANIMALIA; BACTERIA (MICROORGANISMS); RATTUS; RODENTIA;

EID: 78049420276     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.09.027     Document Type: Article

References (23)

1. Akaza H., Miyanaga N., Takashima N., Naito S., Hirao Y., Tsukamoto T., Fujioka T., Mori M., Kim W.J., Song J.M., Pantuck A.J. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn. J. Clin. Oncol. 2004, 34:86-89.
2. Atkinson C., Frankenfeld C.L., Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp. Biol. Med. 2005, 230:155-170.
3. Cheng G., Wilczek B., Warner M., Gustafsson J.A., Landgren B.M. Isoflavone treatment for acute menopausal symptoms. Menopause 2007, 14:468-473.
4. Di Virgilio A.L., Iwami K., Wätjen W., Kahl R., Degen G.H. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicol. Lett. 2004, 151:151-162.
5. + reversion in Escherichia coli. Mutat. Res. 1976, 38:3-32.
6. International Conference on Harmonization., (1997). Guidance on genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. US FDA Fed. Reg. 62, 62471-62475.
7. Jackson, R.L., Greiwe, J.S., Desai, P.B., Schwen, R.J., 2010. Single-dose and multi-dose 14 day pharmacokinetics studies of S-equol, a potent non-hormonal, estrogen receptor β agonist being developed for the treatment of menopausal symptoms. Menopause 18, in press.
8. Jou H.J., Wu S.C., Chang F.W., Ling P.Y., Chu K.S., Wu W.H. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int. J. Gynecol. Obstet. 2008, 102:44-49.
9. Lehmann L., Esch H.L., Wagner J., Rohnstock L., Metzler M. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of daidzein in cultured human Ishikawa cells. Toxicol. Lett. 2005, 158:72-86.
10. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113:173-215.
11. Marrian G., Haslewood G. Equol, a new inactive phenol isolated from the ketohydroxyoestrin fraction of mares urine. Bichem. J. 1932, 26:1227-1232.
12. Muthyala R.S., Ju Y.H., Sheng S., Williams L.D., Doerge D.R., Katzenellenbogen B.S., Helferich W.G., Katzenellenbogen J.A. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg. Med. Chem. 2004, 12:1559-1567.
13. Proudlock R.J., Statham J., Howard W. Evaluation of the rat bone marrow and peripheral blood micronucleus test using monocrotaline. Mutat. Res. 1997, 392:243-249.
14. Schmitt E., Metzler M., Jonas R., Dekant W., Stopper H. Genotoxic activity of four metabolites of the soy isoflavone daidzein. Mutat. Res. 2003, 542:43-48.
15. Setchell K.D.R., Clerici C., Lephart E.D., Cole S.J., Heenan C., Castellani D., Wolfe B.E., Nechemias-Zimmer L., Brown N.M., Lund T.D., Handa R.J., Heubi J.E. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am. J. Clin. Nutr. 2005, 81:1072-1079.
16. Setchell K.D., Brown N.M., Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 2002, 132:3577-3584.
17. Uesugi S., Watanabe S., Ishiwata N., Uehara M., Ouchi K. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Biofactors 2004, 22:221-228.
18. Uchiyama S., Ueno T., Masaki K., Shimizu S., Aso T., Shirota T. The cross-sectional study of the relationship between soy isoflavones, equol and the menopausal symptoms in Japanese women. J. Jpn. Menopause Soc. 2007, 15:28-37.
19. United States Patent 7,528,267: Method for Enantioselective Hydrogenation of Chromenes, Issued May 5, 2009.
20. Vatanparast H., Chilibeck P.D. Does the effect of soy phyto-estrogens on bone in postmenopausal women depend on the equol-producing phenotype?. Nutr. Rev. 2007, 65:294-299.
21. Wakata A., Miyamae Y., Sato S., Suzuki T., Morita T., Asano N., Awogi T., Kondo K., Hayashi M. Evaluation of the rat micronucleus test with bone marrow and peripheral blood: summary of the 9th collaborative study by CSGMT/JEMS MMS. Environ. Mol. Mutagen 1998, 32:84-100.
22. Wu J., Oka J., Ezaki J., Ohtomo T., Ueno T., Uchiyama S., Toda T., Uehara M., Ishimi Y. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 2007, 14:1-9.
23. Yee S., Burdock G.A., Kurata Y., Enomoto Y., Narumi K., Hamada S., Itoh T., Shimomura Y., Ueno T. Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem. Toxicol. 2008, 46:2713-2720.